HK Stock Market Move | HBM HOLDINGS-B (02142) rose by over 4% in the afternoon, potential opposition to BIC, first case of HBM7575 included.

HBM HOLDINGS-B (02142) rose more than 4% in the afternoon and, at the time of writing, was up 3.94% to 14.23 Hong Kong dollars, with a turnover of 40.94 million Hong Kong dollars. On the news front, recently, HBM7575, a long-acting bispecific antibody targeting TSLP of and another undisclosed target of Polphe Pharmaceuticals, completed the first subject enrollment in Phase I clinical trial (CTR20260913), officially entering the clinical validation stage of the dual-targeted and long-acting immuno-oncology pathway. It is worth noting that in January 2025, HBM9378 was licensed to Windward Bio in a NewCo model with a total upfront and milestone payment of up to $970 million, and the latter has initiated the global Phase II POLARIS trial. Leveraging this successful experience, HBM7575 is expected to bring more strategic value to the company through global collaborations, and its subsequent development progress is worth looking forward to.